Avi Nova's questions to Ionis Pharmaceuticals Inc (IONS) leadership • Q3 2024
Question
Speaking for Mike Ulz, Avi Nova asked about the olezarsen launch in FCS, inquiring about the number of patients identified and Ionis's confidence in securing market share before a competitor enters. He also asked how quickly patients in early access programs could be transitioned to the commercial drug.
Answer
CEO Brett Monia stated that the sales and medical affairs teams are actively identifying patients and that the company's 9+ month head start is a key advantage for securing a bolus of patients at launch. He and Chief Global Product Strategy Officer Kyle Jenne added that a rapid transition from early access to commercial drug is planned post-approval via a dedicated patient support program, initially for U.S. patients.